In his role as CEO, Gabe draws on broad experience in both biology and technology to advance Freenome’s mission of giving everyone the tools they need to detect, treat, and ultimately prevent their diseases.
Along with co-founder Riley Ennis, Gabe believes that forging a strong culture is essential to helping Freenome achieve its goals—normalizing mistakes in order to better learn from them, and incorporating core values of empathy, integrity, and trust into every aspect of Freenome’s work.
Gabe holds undergraduate degrees in biology and chemistry from Cornell University. His interest in chromatin biology and the epigenetics of age-associated diseases during graduate studies culminated in the publication of several papers on the application of machine learning to large genomics datasets. In 2014, Gabe founded Acorn, a location-based messaging service, following work as a software engineer at Apple, Glyde, and Tumblr.
With the knowledge and skills he gained as a biotechnology entrepreneur, Riley is helping to make Freenome’s vision of a cancer-free world a reality. As the company’s co-founder and Chief Operating Officer, Riley heads the clinical and commercial development of Freenome’s noninvasive tests for early cancer detection and treatment selection.
A Thiel Fellow, Riley developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. While earning his degree in molecular biology at Dartmouth, Riley co-authored several publications and worked as a visiting scientist with Novartis.
In addition to his work as a scientist, Riley worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of a strong organizational culture firsthand. Riley’s previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.
As Freenome’s Chief Medical Officer, Girish oversees the clinical validation of Freenome’s blood tests and helps navigate the regulatory and financial complexities of the healthcare industry. As director of laboratory science for Palmetto GBA’s MolDX program, Girish continues to oversee coverage and reimbursement for molecular testing for approximately half of the Medicare population.
Girish has held senior leadership roles, including founding laboratory director and Chief Medical Officer, at Ariosa Diagnostics, Crescendo Bioscience, Life Technologies, and VitaPath Genetics. His entrepreneurial experience at Panorama Capital and RiverVest Venture Partners included investments in biopharmaceuticals, medical devices, and diagnostics and services. He served on the boards of portfolio companies, Presidio Pharmaceuticals, PowerVision, and Phenomix.
Girish holds an MD in molecular neuroscience from Washington University in St. Louis, and completed his fellowship in molecular genetic pathology at Stanford University.
In his role as Chief Scientific Officer, Imran leads a cross-functional team of experts in biology, machine learning, and data science in the research and development of Freenome’s advanced AI genomics platform.
As Vice President of Scientific Affairs at Counsyl, Imran led publications and early technology development in reproductive and cancer genetics, translating genetic datasets from hundreds of thousands of individuals into new discoveries for population health. His experience developing a prototype liquid biopsy test for oncology highlighted the challenges of sequencing circulating tumor DNA and ultimately led to his current interest in studying immunologic response as a more promising avenue for early cancer detection.
Imran earned his PhD in computer science at Stanford University, advised by Vijay Pande and Daphne Koller, with a focus on large-scale machine learning for drug discovery. Imran holds a BS in electrical engineering and computer science from the University of California at Berkeley.
Mike brings over 2 decades of experience to his role as Freenome’s Chief Commercial Officer, building on a proven track record of delivering transformative diagnostic technologies to help clinicians drive better outcomes for their patients. At Freenome, Mike is focused on building a commercial team and making our first early-detection test as broadly accessible to providers and patients as possible.
Mike comes to Freenome from Foundation Medicine, where he served as SVP of Commercial Operations and led a cross-functional team to expand the use of next-generation sequencing technologies in cancer. Experience in past roles at Thermo Fisher, Luminex, Roche Molecular Systems, Roche Diagnostics, and Abbott Diagnostics included general management and commercial leadership of teams and bringing innovative technologies to mainstream utilization in clinical care
Mike holds a B.S. in Biological Sciences and a MBA from the University of Wyoming.
A clinician by training, Charlie is Freenome’s Chief Partnership Officer, focusing on mid- and longer-term relationships that will help define the company’s future directions and revenues and works closely with the business development team in managing corporate client accounts and institutional collaborations.
Prior to co-founding Freenome, Charlie co-founded a company that uses circulating cell-free (cf)DNA from maternal blood samples to diagnose chromosomal abnormalities during pregnancy. The resulting in-vitro diagnostic, IONA, has been marketed successfully across Europe and the Middle East.
Charlie studied medicine and neuropsychology in the UK, earning a Masters degree from Oxford with a focus on immunotherapy. He has worked in some of the UK’s leading oncology centers, including the Royal Marsden.
An internal medicine-trained physician and healthtech expert with seventeen years experience in medical marketing and healthcare strategy, Lena serves as Freenome’s Vice President of Marketing. In this role, Lena helps translate complex medical concepts and value propositions into compelling, inspiring marketing strategies to help diverse audiences understand how Freenome’s breakthrough technology can improve patient outcomes and lower healthcare costs.
Prior to joining Freenome, Lena was the vice president of enterprise marketing at Doctor On Demand, the country’s leading video telemedicine company. A key member of the leadership team, Lena helped to scale Doctor On Demand’s partnerships with self-insured employers and health plans.
Lena earned an MD from the Northwestern University Feinberg School of Medicine in the honors program in medical education.
As Freenome’s head of lab and technology operations, Dan is focused on building a technology-first laboratory from the ground up, supporting the development of a new generation of artificial intelligence-powered tests that will shift the focus of medicine from managing illness to preserving health.
Prior to Freenome, Dan led the lab automation team at Guardant Health, where he designed, built, and validated the liquid biopsy sample-processing pipeline from the ground up, enabling rapid scaling of sample processing volumes, while his work optimizing assay bio-chemistry improved both robotic and operational performance. As automation engineering lead at Counsyl, Dan built the first blood-to-data, fully-automated molecular biology sample processing pipeline for clinical use in the world. To this day, the system serves as the gold-standard reference for laboratory efficiency.
Dan earned his PhD in bioengineering and biomedical engineering from Carnegie Mellon University.
As head of business development, Blandine is focused on growing and maintaining strategic partnerships with bio-pharmaceutical and academic organizations in the development of the next generation of genomic screening tools and precision oncology therapies.
Before joining Freenome, Blandine was the head of pharma alliance management at Guardant Health, where she oversaw rapid revenue growth, and spent and oversaw product portfolio management at Kraft for more than a decade. In her role as Director of Alliance Management at Alkahest, Blandine cultivated strong relationships with strategic investors and streamlined a framework for strategic financial planning.
Blandine holds an MS in molecular biology from Paris-Sud University and an MS in engineering and management from ISA Engineering and Business School.
In his role as head of engineering at Freenome, Alex leads the development of large-scale data processing and database systems to support the AI genomic analysis of the vast data sets needed to make sense of the tumor microenvironment. It’s a foundational step in isolating the complex biomarkers patterns that allow Freenome to pinpoint cancer at its earliest stages.
Prior to Freenome, Alex was one of the early engineers at Trifacta, the enterprise data preparation company, where he led development of their cloud-based application to clean up and prepare messy, diverse data quickly and accurately. Alex also led the backend development of Google Cloud Dataprep, Trifacta’s integration with the Google Cloud Platform.
Alex earned his PhD in computer science and engineering from University of California at San Diego. His dissertation, focused on efficient large-scale data processing, led to the creation of TritonSort, which set several world records in large-scale sorting.
In his role as head of regulatory affairs Abe draws on his prior experience as a medical officer at the U.S. Food and Drug Administration (FDA) to develop and implement product regulatory strategies and manage submissions to FDA and other regulatory authorities on behalf of Freenome.
At the FDA, Abe led the clinical evaluation of in-vitro diagnostic devices for cancer screening, companion diagnostics, cancer prognosis, genetic disorders, and other emerging diagnostic tests. While at the FDA, Abe earned recognition for sustained and superior contributions to developing innovative approaches for molecular genetics and pathology devices, as well as a special citation for contributions to the premarket approval for a BRAC analysis companion diagnostic.
Abe holds an MD and bachelor degrees in biomedical engineering and biological sciences from Northwestern University. He trained in clinical pathology at Yale University.